ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol.

ABSTRACT:

Introduction

Sepsis is a major cause of death among hospitalised patients. Accumulating evidence suggests that immune response during sepsis cascade lies within a spectrum of dysregulated host responses. On the one side of the spectrum there are patients whose response is characterised by fulminant hyperinflammation or macrophage activation-like syndrome (MALS), and on the other side patients whose immune response is characterised by immunoparalysis. A sizeable group of patients are situated between the two extremes. Recognising immune endotype is very important in order to choose the appropriate immunotherapeutic approach for each patient resulting in the best chance to improve the outcome.

Methods and analysis

ImmunoSep is a randomised placebo-controlled phase 2 clinical t

SUBMITTER: Kotsaki A 

PROVIDER: S-EPMC9772655 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature